文献速递前列腺癌

纳入多参数磁共振的前列腺癌风险计算器的外部验证与比较

External Validation and Comparison of Prostate Cancer Risk Calculators Incorporating Multiparametric Magnetic Resonance Imaging for Prediction of Clinically Significant Prostate Cancer.
PubMed 文献 · J Urol · 2019-10-25

该研究在468例无前列腺癌史并接受经会阴模板饱和穿刺联合融合靶向穿刺的男性中,外部验证了4个纳入多参数磁共振的前列腺癌风险计算器和2个未纳入多参数磁共振的计算器。193例(41%)诊断为临床显著前列腺癌。3个纳入多参数磁共振的计算器区分度相似,ROC AUC为0.83-0.85,显著高于其他计算器的0.69-0.74;仅这3个计算器在穿刺阈值15%或以上时显示临床净获益。

要点

  • 纳入多参数磁共振的前列腺癌风险计算器区分度优于未纳入者(AUC 0.83-0.85 vs 0.69-0.74)。
  • 仅3个纳入多参数磁共振的计算器在穿刺阈值≥15%时显示临床净获益。
  • 所有6个计算器在阈值<15%时均未优于全部穿刺策略。

核心结论

  • 纳入多参数磁共振的前列腺癌风险计算器性能不一,但总体在区分度、校准和临床实用性上优于未纳入多参数磁共振的计算器。
  • 鼓励在其他穿刺设置中进行外部验证。

研究设计与样本

  • 外部验证研究,纳入2014年11月至2018年3月在一家学术三级转诊中心接受经会阴模板饱和穿刺联合融合靶向穿刺、无前列腺癌病史的男性468例。
  • 临床显著前列腺癌定义为任何Gleason模式4或以上。
  • 评估4个纳入多参数磁共振的前列腺癌风险计算器和2个未纳入多参数磁共振的计算器,指标包括区分度、校准和临床净获益。

主要发现

  • 468例中193例(41%)诊断为临床显著前列腺癌。
  • 3个纳入多参数磁共振的计算器区分度相似,ROC AUC为0.83-0.85,显著高于其他计算器的0.69-0.74。
  • 2个纳入多参数磁共振的计算器校准偏差为2%,其他计算器校准较差,偏差为11%至27%。
  • 仅3个纳入多参数磁共振的计算器在穿刺阈值15%或以上时观察到临床净获益。
  • 所有6个计算器在阈值小于15%时均未显示相对于全部穿刺策略的临床实用性。

关键数值与推荐

  • 临床显著前列腺癌定义:任何Gleason模式4或以上。
  • 区分度:3个纳入多参数磁共振的计算器ROC AUC 0.83-0.85,其他计算器0.69-0.74。
  • 校准:2个纳入多参数磁共振的计算器偏差2%,其他计算器偏差11%至27%。
  • 临床净获益:仅3个纳入多参数磁共振的计算器在穿刺阈值≥15%时观察到。

临床怎么用

  • 在决策是否进行前列腺穿刺时,可优先考虑纳入多参数磁共振的风险计算器以提升区分度和校准。
  • 在穿刺阈值15%或以上时,部分纳入多参数磁共振的计算器可提供临床净获益。
  • 在阈值低于15%时,所评估的6个计算器均未优于全部穿刺策略,需谨慎解读。

局限性

  • 研究为单中心学术三级转诊中心的外部验证,结果外推需谨慎。
  • 作者鼓励在其他穿刺设置中进行外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We sought to externally validate recently published prostate cancer risk calculators incorporating multiparametric magnetic resonance imaging to predict clinically significant prostate cancer. We also compared the performance of these calculators to that of multiparametric magnetic resonance imaging naïve prostate cancer risk calculators. MATERIALS AND METHODS: We identified men without a previous prostate cancer diagnosis who underwent transperineal template saturation prostate biopsy with fusion guided targeted biopsy between November 2014 and March 2018 at our academic tertiary referral center. Any Gleason pattern 4 or greater was defined as clinically significant prostate cancer. Predictors, which were patient age, prostate specific antigen, digital rectal examination, prostate volume, family history, previous prostate biopsy and the highest region of interest according to the PI-RADS™ (Prostate Imaging Reporting and Data System), were retrospectively collected. Four multiparametric magnetic resonance imaging prostate cancer risk calculators and 2 multiparametric magnetic resonance imaging naïve prostate cancer risk calculators were evaluated for discrimination, calibration and the clinical net benefit using ROC analysis, calibration plots and decision curve analysis. RESULTS: Of the 468 men 193 (41%) were diagnosed with clinically significant prostate cancer. Three multiparametric magnetic resonance imaging prostate cancer risk calculators showed similar discrimination with a ROC AUC significantly higher than that of the other prostate cancer risk calculators (AUC 0.83-0.85 vs 0.69-0.74). Calibration in the large showed 2% deviation from the true amount of clinically significant prostate cancer for 2 multiparametric magnetic resonance imaging risk calculators while the other calculators showed worse calibration at 11% to 27%. A clinical net benefit was observed only for 3 multiparametric magnetic resonance imaging risk calculators at biopsy thresholds of 15% or greater. None of the 6 investigated prostate cancer risk calculators demonstrated clinical usefulness against a biopsy all strategy at thresholds less than 15%. CONCLUSIONS: The performance of multiparametric magnetic resonance imaging prostate cancer risk calculators varies but they generally outperform multiparametric magnetic resonance imaging naïve prostate cancer risk calculators in regard to discrimination, calibration and clinical usefulness. External validation in other biopsy settings is highly encouraged.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Saba K, Wettstein MS, Lieger L, et al. External Validation and Comparison of Prostate Cancer Risk Calculators Incorporating Multiparametric Magnetic Resonance Imaging for Prediction of Clinically Significant Prostate Cancer. J Urol. 2019. PMID: 31651228. doi:10.1097/JU.0000000000000622

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。